Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

 

Subscribe To Our Latest Investor News

News Highlights
May 27, 2021

Bayer announces five-point plan to effectively address potential future Roundup™ claims

Read more
May 25, 2021

Precision oncology treatment Larotrectinib submitted for marketing authorization in China

READ MORE
May 21, 2021

Positive CHMP opinion for Bayer’s new symptomatic chronic heart failure treatment vericiguat

READ MORE
May 19, 2021

Long-term data on Vitrakvi™ (larotrectinib) confirm sustained clinical benefit

READ MORE
AD HOC

Discover Bayer’s Latest Ad Hoc Releases

READ MORE
Explore All
1 - 10of about 624 News
1 - 10of about 624 News
June 03, 2021
Not intended for U.S. and UK Media
Bayer acquires Noria and PSMA Therapeutics to expand portfolio in prostate cancer
READ MORE
May 27, 2021
Bayer announces five-point plan to effectively address potential future Roundup™ claims
READ MORE
May 25, 2021
Not intended for U.S. and UK Media
Precision oncology treatment Larotrectinib submitted for marketing authorization in China
READ MORE
May 21, 2021
Not intended for U.S. and UK Media
Positive CHMP opinion for Bayer’s new symptomatic chronic heart failure treatment vericiguat
READ MORE
May 19, 2021
Not intended for U.S. and UK Media - ASCO Annual Meeting 2021:
Long-term data on Vitrakvi™ (larotrectinib) confirm sustained clinical benefit of greater than four years in patients with TRK fusion cancer regardless of tumor type and age
READ MORE
May 17, 2021
BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases
READ MORE
May 17, 2021
Not intended for U.S. and UK Media - Late-Breaking Data from exploratory analysis of Phase III FIDELIO-DKD study presented at the American College of Cardiology’s (ACC) 70th Annual Scientific Session (ACC.21)
Finerenone has potential to reduce the risk of new onset atrial fibrillation or flutter in patients with chronic kidney disease and type 2 diabetes
READ MORE
May 12, 2021
First quarter of 2021:
Bayer: successful start to 2021
READ MORE
May 11, 2021
Not intended for U.S. and UK Media
Bayer presents expanded research and new approaches to advance cancer care at 2021 ASCO Annual Meeting
READ MORE
May 10, 2021
Not intended for U.S. and UK Media
Bayer’s finerenone meets primary endpoint in Phase III FIGARO-DKD cardiovascular outcomes study in patients with chronic kidney disease and type 2 diabetes
READ MORE
1 - 10of about 624 News
1 - 10of about 624 News